You are here: Industry Insights > Lenvima

News List

Keytruda/Lenvima combo shows promise in hard-to-treat cancers pharmatimes
September 22, 2020
MSD (Merck) and Eisai have revealed new data from two trials under the LEAP clinical programme evaluating the combination of MSD’s PD-1 inhibitor Keytruda and Eisai’s oral tyrosine kinase inhibitor Lenvima.
US rejects MSD/Eisai's Keytruda Lenvima combo pharmatimes
July 10, 2020
MSD and Eisai have received a complete response letter (CRL) from the US Food and Drug Administration rejecting accelerated approval of a combination of Keytruda (pembrolizumab) and Lenvima (lenvatinib) for liver cancer.
US FDA declines to approve Merck and Eisai’s liver cancer combo therapy expresspharma
July 10, 2020
The FDA's complete response letter cited lack of sufficient evidence that the Keytruda-Lenvima combination therapy had a meaningful advantage over available treatments for the condition.
FDA Approves Keytruda (pembrolizumab) plus Lenvima (lenvatinib) Combination Treatment for Patients with Certain Types of Endometrial Carcinoma drugs
September 23, 2019
Merck, known as MSD outside the United States and Canada, and Eisai today announced that the U.S. Food and Drug Administration (FDA) approved the combination of Keytruda ...
EISAI launches Lenvima in China biospectrumasia
November 19, 2018
In addition to China, LENVIMA is approved for use in the treatment of HCC in Japan, the United States, Europe, and other
EISAI launches Lenvima in China biospectrum
November 13, 2018
In addition to China, LENVIMA is approved for use in the treatment of HCC in Japan, the United States, Europe, and other countries in Asia and around the world
Eisai's Lenvima gets nod in China for liver cancer treatment biospectrumasia
September 07, 2018
HBV is considered to be a negative predictor of tumor response to existing drug therapies.
Eisai, Merck & Co. bag EU approval for Lenvima in unresectable HCC, days after US nod firstwordpharma
August 24, 2018
Eisai and Merck & Co. reported Thursday that the European Commission approved Lenvima (lenvatinib) as a single agent for the first-line treatment of adults with advanced or unresectable hepatocellular......
Eisai gets marketing approval from EC for LENVIMA biospectrumasia
August 24, 2018
As First-Line Treatment in Adults with Advanced or Unresectable Hepatocellular Carcinoma
Eisai, Merck Announce FDA Approval of Lenvima fiercepharma
August 20, 2018
Eisai and Merck announced the U.S. Food and Drug Administration (FDA) approved the kinase inhibitor Lenvima (lenvatinib) for the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC).

Previous page 1 2 3 Next page